HLX43
Based on 1 Customer Validation
HLX43 is an antibody-drug conjugate (ADC) targeting PD-L1. HLX43 consists of a human monoclonal antibody anti-PD-L1 antibody Opucolimab (HY-P99785) with the drug-linker conjugate being DL-01 (HY-155870A). HLX43 exerts superior anticancer efficacy with safety profile in vivo. HLX43 can be used for non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), esophageal squamous cell carcinoma (ESCC), melanoma (MEL), ovarian cancer (Ovc) research.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.60%
- Masse moléculaire:153714 (average)
-
Stockage:
-80°C, protect from light
Activité biologique
HLX43 induces tumor regression in multiple PD-L1+ CDX and PDX models, and was well tolerated across all dosing groups[2].
HLX43 (8 mg/kg, three times for a week) significantly reduces tumors in the MDA-MB-231 model without causing weight loss[2].
HLX43 shows well tolerability in rats and cynomolgus monkeys, with the maximum tolerated dose being 60 mg/kg in rats and 10 mg/kg in non-human primates[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
Appearance Liquid
-
Masse moléculaire 153714 (average)
-
Color Colorless to light yellow
-
SMILES
[HLX43]
-
Livraison
Shipping with dry ice.
-
Stockage
-80°C, protect from light
Pureté et documentation
-
Fiche technique (267 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Instruction de manipulation (2659 KB)
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)